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In mammals, >100 genes regulate pigmentation by means of a
wide variety of developmental, cellular, and enzymatic mecha-
nisms. Nevertheless, genes that directly regulate pheomelanin
production have not been described. Here, we demonstrate that
the subtle gray (sut) mouse pigmentation mutant arose by means
of a mutation in the Slc7a11 gene, encoding the plasmamembrane
cystineglutamate exchanger xCT [Kanai, Y. & Endou, H. (2001)
Curr. DrugMetab. 2, 339–354]. A resulting low rate of extracellular
cystine transport into sut melanocytes reduces pheomelanin pro-
duction. We show that Slc7a11 is a major genetic regulator of
pheomelanin pigment in hair and melanocytes, with minimal or no
effects on eumelanin. Furthermore, transport of cystine by xCT is
critical for normal proliferation, glutathione production, and pro-
tection from oxidative stress in cultured cells. Thus, we have found
that the Slc7a11 gene controls the production of pheomelanin
pigment directly. Cells from sutmice provide a model for oxidative
stress-related diseases and their therapies.
glutathione  melanin  pigmentation  cystine  melanocyte
Pheomelanin (redyellow) pigment is produced by the addi-tion of cysteine to dopaquinone (1). Both pheomelanin and
eumelanin (brownblack) pigments protect skin from UV dam-
age. However, pheomelanin also serves an opposing role as a
potent UV photosensitizer, possibly contributing to increased
sensitivity of fair-skinned individuals with yellow or red hair to
sunburn, premature aging, andor malignant transformation (2).
In mice and other mammals, pheomelanin in the typical agouti-
banding pattern provides camouflage, and in mammals and
birds, pheomelanin pigmentation patterns are important com-
ponents of the mechanisms of sexual recognition and display (3).
It has been suggested, although not proven, that the recessive
subtle gray (sut) mouse pigmentary mutation reduces yellow
pigmentation (4). sut also has moderate deficiencies of electron
microscopically observable platelet-dense granules, qualifying it
as a model (5) for a mild form of Hermansky–Pudlak syndrome
(HPS), a genetically heterogeneous inherited disease character-
ized by abnormalities in biosynthesis andor trafficking of
lysosome-related organelles, including melanosomes, platelet-
dense granules, and lysosomes (6, 7). In mice, at least 16 models
of HPS are known (8). Several HPS genes encode proteins with
known functions in vesicle trafficking such as subunits of the
AP-3 adaptor protein complex, the Rab geranylgeranyltrans-
ferase complex, and the class C protein complex. However, the
majority are genes of unknown function and are found only in
higher metazoans (8).
Materials and Methods
Mice and Genetic Crosses. Mutant sut and control C3HHeSnJ
mice were obtained from The Jackson Laboratory and subse-
quently bred in the animal facilities of Roswell Park Cancer
Institute. All procedures (mouse protocols 125M) were ap-
proved by the Roswell Park Institutional Animal Care and Use
Committee and adhered to the principles of the National Insti-
tutes of HealthGuide for the Care and Use of Laboratory Animals.
Identification of the sut Gene.High-resolution genetic and physical
maps of the sut critical region were generated with a backcross
between homozygous sutsut mice and PWK wild-type mice
(subspecies Mus musculus musculus) as described in ref. 9 and
based on the National Center for Biotechnology Information
map viewer (build 32.1). Altogether, we typed 1,474 backcross
progeny at 6 weeks of age for the sut pigment phenotype and for
crossovers in the region surrounding sut by using the flanking
microsatellites D3Mit3 (proximal) and D3Mit153 (distal).
We used 3 RACE of mouse brain mRNA to find the
alternative 3end of the Slc7a11 mRNA in sut brain (GenBank
accession no. AY766237). Two alternative transcripts in C3H
HeSnJ brain cDNA with different poly(A) signals (GenBank
accession no. AY766236) were identified.
Expression Analysis. Total RNA was reverse transcribed as de-
scribed in ref. 9. For Northern blot analysis of sut transcripts,
poly(A)-mRNA (4 g from brain and 2 g from melanocytes)
was isolated according to Promega PolyATract kit instructions,
blotted, and hybridized with a transcript-specific 300-bp sut
32P-radiolabeled probe (exons 9–11).
Cell Culture. The sut gene was transferred from the C3HHeSnJ
strain to the C57BL6J strain by backcrossing for six generations.
Melanocyte lines from sutsutmutants were generated rapidly by
deriving cell cultures carrying the Ink4a–Arf deletion to prevent
cell senescence, as described in ref. 10. The C57BL6J melan-a
cell line (11) was used as wild-type control. Fibroblasts from skin
of newborn C3HHeSnJ and sut were established as described in
ref. 12. Thioglycollate-elicited mouse peritoneal macrophages
were isolated and cultured as described in ref. 13.
Cell numbers were measured in a Coulter Counter after
trypsinization. Trypan blue assays indicated 95% viability of
sut melanocytes after 1–4 days culture with -mercaptoethanol
(ME), whereas 90% were nonviable after 4 days culture
without ME.
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Rescue of sut Phenotype in Transgenic Mice. We injected bacterial
artificial chromosome (BAC) RP23-2203 into pronuclei derived
from hybrid (C3HHeRos  C57BL10 Rospd) F2 females.
BAC-positive pups were mated with C3HHeSnJ sutsutmice to
produce F1 progeny. BAC-positive F1 pups were backcrossed to
sutsut to produce F2 progeny. Each F2 pup was typed for coat
color, presence of the BAC transgene, and presence of the
deletion in the Slc7a11 gene.
Transport of [35S]Cystine and [3H]Leucine. Melanocytes from wild
type (melan-a) and mutant (sutsut) mice grown with ME were
rinsed three times in warm PBSG [10 mM sodium phosphate
137 mM NaCl3 mM KCl (pH 7.4), containing 0.9 mM CaCl2,
0.49 mMMgCl26H2O, and 5.6 mM glucose], and then incubated
in uptake medium {PBSG containing [35S]cystine (10 Ci0.5
ml; 1 Ci  37 GBq), [3H]leucine (1 Ci0.5 ml), and unlabeled
leucine (10 M), with or without ME}. The specificity of the
cystine uptake system was determined in the presence of 2.5 mM
unlabeled glutamic acid and arginine, separately.
Melanin Analysis. Eumelanin and pheomelanin were quantita-
tively analyzed (14) by HPLC based on the formation of pyrrole-
2,3,5-tricarboxylic acid (PTCA) by permanganate oxidation of
eumelanin and 4-amino-3-hydroxyphenylalanine (4-AHP) by
hydriodic acid reductive hydrolysis of pheomelanin, respectively
(1). These specific degradation products were determined by
HPLC.
HPLC Analysis of Glutathione. Glutathione was analyzed by HPLC
(15). To correct for the artifactual oxidation of glutathione, an
aliquot of each sample was treated with 5% perchloric acid in the
presence of 50 mM N-ethylmaleimide and analyzed in parallel.
Screening of HPS Patients. RNA was isolated from cultured fibro-
blasts of 15 HPS patients enrolled in a protocol approved by the
National Institute of Child Health andHumanDevelopment and
the National Human Genome Research Institute institutional
review boards to study the clinical and molecular aspects of HPS.
Mutation analysis for human SLC7A11 was performed on each
patient’s cDNA (transcribed from RNA by using Superscript
RT-PCR, Invitrogen) in three overlapping fragments by using
standard PCR and sequencing conditions.
PCR products spanning the 13 exons of SLC7A11 plus the
adjacent intron and noncoding sequences were screened in
Fig. 1. Positional cloning of the sut gene. (A) High-resolution genetic map of the sut genetic interval. (B) High-resolution physical map. Five known genes in
the sut interval are listed with arrowheads indicating transcriptional orientations. (C) Region of the genome between Pcdh18 and Slc7a11. The sut deletion is
depicted by a dashed line. The sizes of introns (lines), exons (boxes), and intergenic regions (bold lines) are given in base pairs. (D) Transcripts of Slc7a11 in sut
and control (C3HHeSnJ) brains identified by 3RACE. In sut, Slc7a11utilizes an alternative exon 12 (E12, open box) from beyond the deleted region. (E) Predicted
proteins, xCT-sut, and xCT-C3H, encoded by transcripts in sut and C3HHeSnJ respectively. The underlined bold residues in xCT-C3H are conserved across species.
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genomic DNA of 17 other HPS patients who likewise lack
mutations in the known human HPS genes plus one normal
Caucasian control.
Dopa Histochemistry and Electron Microscopy. Dopa (3,4-
dihydroxyphenylalanine) histochemistry was carried out by a
method modified from that of Boissy et al. (16). Cells were fixed
in 2.5% glutaraldehyde2% paraformaldehyde in 0.2 M sodium
cacodylate buffer (pH 7.2) for 1 h at room temperature and
washed before incubation in L- or D-dopa (0.1% in cacodylate
buffer) for two 2.5 h intervals at 37°C. (D-dopa staining was used
as a control and produced no stain.) The cells were washed as
before and postfixed in 1% osmium tetroxide with 1.5% potas-
sium ferrocyanide in cacodylate buffer for 1 h at room temper-
ature. Three final washes were carried out before dehydration
and embedding for sectioning.
Results
Positional Cloning of the sut Gene. To obtain a high-resolution
genetic map of the sut gene region on mouse chromosome 3,
1,474 progeny of an interspecific backcross were typed for coat
color (the sut gene) and numerous microsatellite markers. This
backcross defined a 0.12 cM genetic interval (Fig. 1A), consisting
of 3 megabases of DNA containing five predicted genes (Fig.
1B). One gene, Slc7a11, which encodes the xCT cystine
glutamate exchanger (17), produced no product on amplification
of sut cDNA by RT-PCR using primers from exons 1 and 12.
Sequencing revealed a large deletion (481,280 bp) extending
from intron 11 through exon 12 and into the sut intergenic region
adjacent to the Pcdh18 gene (Fig. 1C), creating a new splice site
and replacement of exon 12 with exon 12 (E12, Fig. 1 C andD).
3 RACE revealed a new stop codon in exon 12 and predicted
a modified and truncated protein carboxyl terminus (Fig. 1E).
Deficiency of Expression of Slc7a11 in sut Mice and Its Effect on
Pigmentation in sut and Transgenic Mice. Northern blot analyses of
poly(A)-RNA from normal and sut-mutant brain and melano-
cytes demonstrated a marked deficiency of the 9-kb (brain) (18)
and 9.5-kb (melanocyte) Slc7a11 mRNA transcripts in sutsut
(Fig. 2A). We confirmed the identification of sut as Slc7a11 by
rescuing the sut-mutant phenotype by inserting wild-type
Slc7a11 into the genome of sut-mutant transgenic mice. BAC
RP23-22O3, which exclusively contains the Slc7a11 gene, re-
stored normal agouti pigmentation to sut mutants (Fig. 2B),
demonstrating Slc7a11 is critical for pheomelanin production
and is the bona fide sut gene.
To provide clear visualization of the role of the Slc7a11 gene
in pheomelanin production, we transferred the sut allele to a
stock containing the semidominant ‘‘yellow’’ (Ay) allele, which is
conspicuously yellow because of constitutive expression of the
agouti locus (19). Their intense pheomelanic pigmentation was
muted to a light cream color when the mouse was also homozy-
gous for sut (Fig. 2C), indicating that loss of expression of
Slc7a11 causes marked inhibition of pheomelanogenesis.
Control of Pheomelanin Levels by Slc7a11. To quantify the effect of
lost Slc7a11 expression on pheomelanin production, we analyzed
eumelanin and pheomelanin by HPLC in hair of C3H ,
sut, and sutsut mice. The agouti (AA) genotype of these
mice produces both eumelanin and pheomelanin in hair. Hair
from sut mutants contained only 40% normal pheomelanin
levels with no significant effect on eumelanin, and normal
pheomelanin levels were restored in sut mice transgenic for the
wild-type Slc7a11 gene (Table 1). The effect of the Slc7a11 sut
mutation on pheomelanin production was markedly accentuated
on the Aya background, reducing pheomelanin levels to 20%
of the control level. Also, the low level of eumelanin was
increased 4-fold on loss of Slc7a11 expression. We likewise
observed a large reduction in pheomelanin in cultured sut
melanocytes (Table 2), which also exhibited an increase in
eumelanin, making them among the most eumelanic of cultured
melanocytes thus far examined (20). Combined genetic, trans-
genic rescue, and biochemical data therefore provide compelling
evidence that the Slc7a11 xCT transporter is critical for the
production of pheomelanin.
Fig. 2. Altered regulation of Slc7a11 in sut mutants. (A) Northern blots of
poly(A)-mRNA were probed with labeled Slc7a11 (Upper) and -actin (Lower)
cDNAs. (B) One transgenic rescued sutsut agouti pup (positive for BAC
RP23-22O3, which contains Slc7a11) plus a sutsut littermate and a heterozy-
gous (sut) control. Note agouti color in BAC-positive pup compared with
the gray color of sutsut pup. (C) There is a near-complete loss of yellowred
(pheomelanin) pigment in sutsut, Aya mutants compared with the ,
Aya controls.
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Slc7a11 Mutation Reduces Cystine Transport into Melanocytes and
Other Cells.A possible explanation for pheomelanin deficiency in
sut mice is that loss of Slc7a11 reduces transport of cystine into
melanocytes. Indeed, transport of radiolabeled cystine into
sut-mutant melanocytes was depressed to 20–30% of control
rates (Fig. 3A). Similarly decreased rates of cystine transport
were observed in sut-mutant macrophages. The effect of the
Slc7a11 mutation is specific because there was no diminution in
uptake of [3H]leucine (Fig. 3A) or [35S]cysteine (data not
shown). Inhibition of transport of [35S]cystine into wild-type
(melan-a) melanocytes by glutamate, but not arginine (Fig. 3A),
confirms that these measurements are specific for the Slc7a11
xCT transporter (21).
Transport of Cystine by the xCT Transporter Is Necessary for Survival
and Proliferation of Cells Under Normal Culture Conditions. Sulfhy-
dryl amino acids exist almost entirely in their oxidized form
under normal culture conditions (17, 21). We hypothesized
therefore that viability of cultured sut cells would be adversely
affected, because they likely do not transport cystine intracel-
lularly at a rate sufficient for survival. In fact, sut melanocytes
grew very poorly under normal culture conditions, and growth
was improved, to essentially normal rates, by supplementation of
the medium with a sulfhydryl reducing agent, ME (Fig. 3B).
Without ME, these cells featured aberrant dendritic morphol-
ogy, and 90% were nonviable by trypan blue staining after 4
days in culture. It seems likely that ME improves growth by
preventing oxidation of cysteine, which is transported at normal
rates (see Slc7a11 Mutation Reduces Cystine Transport into
Melanocytes and Other Cells) in sut cells by alternative systems
such as the alanine–serine–cysteine transporter (17). We ob-
served similar reductions in cell proliferation and survival under
normal oxidizing conditions and restoration to normal rates
under reducing conditions, for sut fibroblasts (Fig. 3B). Further,
we observed an intermediate growth rate of sut fibroblasts
minus ME, indicating that reduced xCT protein produced in
heterozygous cells is limiting for cystine uptake and utilization.
The xCT Transporter Maintains Normal Glutathione Levels. Cysteine
is a component of the tripeptide glutathione, which is critically
important in the control of harmful reactive oxygen species. No
glutathione was detectable in sut melanocytes grown without
ME (Fig. 4). Glutathione in sut melanocytes cultured with
ME was measurable but lower than in wild-type melanocytes.
These results emphasize the importance of the xCT transporter
in maintaining normal glutathione concentration and provide a
rationale for the loss of viability of sut cells cultured under
normal oxidizing conditions.
Slc7a11 Regulates Tyrosinase Transport in Melanocytes. The mor-
phology and melanosome density of cultured immortalized sut
melanocytes appeared similar to those of control melanocytes by
light microscopy (Fig. 5), although clusters of melanosomes were
more prevalent on ultrastructural analysis than in control cells
(data not shown). Dopa-staining indicated an abnormal accu-
mulation of the enzyme tyrosinase in tubular perinuclear struc-
tures, possibly the trans-Golgi network (Fig. 6A). This accumu-
lation was not seen in wild-type cells or in sut cells grown with
ME (Fig. 6B), which had a normal distribution of dopa stain in
transport vesicles and melanosomes. Hence, at least a portion of
Fig. 3. Cystine transport and growth are reduced in cultured sut cells. (A
Upper) [35S]Cystine transport was measured in melanocytes and macrophages
from  (Œ) and sutsut () mice cultured under normal oxidizing condi-
tions. Effects of 2.5 mM glutamic acid [melan-a  melanocytes (F); sut-
melanocytes ()] and 2.5 mM arginine [melan-a  melanocytes (); sut-
melanocytes (E)] on the transport of [35S]cystine were assayed at 5 min. (A
Lower) [3H]Leucine transport into melanocytes and macrophages. Values are
the average of duplicates from a representative experiment. (B) Growth of sut
cells is attenuated under oxidizing culture conditions. Fibroblasts and mela-
nocytes were grown with () and without () ME. Values are the average of
duplicates from a representative experiment.
Table 1. Melanin analyses of hair
Mice
Pheomelanin,
gmg
Eumelanin,
gmg
Pheomelanin
eumelanin
C3H  3.80  0.398 53.6  5.18 0.073
C3H sut 3.77  0.302 75.7  3.10 0.051
C3H sutsut 1.55  0.212* 75.9  5.01 0.033
C3H sutsut
 BAC RP23–2203
4.77  1.00 62.9  2.33 0.077
B6 Aya  40.5  2.11 0.523  0.127 92.2
B6 Aya, sutsut 7.27  0.908** 2.138  0.418* 4.4
Values are mean  SEM of 3 or 4 samples. *, P  0.05; **, P  0.001
compared with  mice of the same strain.
Table 2. Melanin analyses of cultured melanocytes
Melanocytes
Pheomelanin,
gmg of
protein
Eumelanin,
gmg of
protein
Pheomelanin
eumelanin
Plus ME
Melan-a 9.14  0.47 88.9  18.5 0.103
sut 0.80  0.08** 404  29.9** 0.0020
Minus ME
Melan-a 22.6  2.3 196  25 0.115
sut 1.67  0.44** 990  289** 0.0017
Melan-a and sut melanocytes were cultured with 100 M ME until they
reached 80–90% confluency. Thereupon, cells were split and cultured in the
presence (plus ME) or absence (minus ME) of ME for 1 day before analysis.
Values are mean SEM of 3 or 4 samples.**,P0.001 compared with melan-a
mice.
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this melanosomal enzyme undergoes abnormal trafficking in sut
cells grown without ME.
Screening for SLC7A11 Mutations in HPS Patients. In the mouse, sut
is 1 of at least 16 pigmentation mutants that provide models for
human HPS (8). Accordingly, we screened for human SLC7A11
(gI no. 18141306) mutations in 32 patients with features of HPS
who lack mutations in the seven known human HPS loci.
Although a number of nonpathological SNPs were observed, no
deleterious mutations were found.
Discussion
A current model suggests that the eumelaninpheomelanin ratio
in mammalian pigmentation is controlled solely and indirectly by
modulation of the activity of tyrosinase, the rate-limiting enzyme
for melanin synthesis (22). This model postulates that at low
tyrosinase concentrations dopaquinone reacts in melanosomes
with sulfhydryls such as cysteine, yielding cysteinyl-dopa (1), and
increased quantities of pheomelanin are produced. Although
useful, this model for control of the eumelaninpheomelanin
ratio is incomplete. Our data demonstrate that the xCT trans-
porter is a critical player in the control of pigmentation. How-
ever, unlike tyrosinase, it directly affects pheomelanin produc-
tion with small increases in eumelanin in hair and cultured sut
melanocytes. The loss of yellow pigment in sutmutants indicates
that a critical rate of transport of cystine into melanocytes is
essential for pheomelanin synthesis in vivo. The Slc7a11 gene
directly affects this pheomelanin synthesis pathway. These re-
sults are consistent with biochemical evidence that cysteine is an
important component of pheomelanin (1).
Several genes [melanocortin 1 receptor (Mc1r), pro-opiomela-
nocortin  (Pomc1), agouti (a), attractin (Atrn), and mahogunin
(Mgrn1)] regulate the switching between eumelanin and pheomela-
nin synthesis in mouse hairshafts (23, 24). A knockout of the
-glutamyl transpeptidase gene (25) and a mutation of the gray-
lethal (ostm1) gene (26), which encodes a unique transmembrane
protein (27), apparently affect pheomelanin. Loss of the former
gene indirectly lowers tissue cysteine levels and produces a gray
coat; mutation of the latter causes clumping of pheomelanin
granules and a gray coat. However, hair pheomelanin concentra-
tions were not chemically ascertained in either case.
It is formally possible that the role of xCT, similarly to the
agouti or melanocyte stimulating hormone proteins, is to signal
Fig. 5. Microscopy of wild-type (melan-a, A and C) and sut-mutant (B and D)
melanocytes. (A and B) Bright-field images. (C and D) Dopa-stained cells;
arrows in D indicate the perinuclear distribution of dopa reaction product in
sut cells.
Fig. 4. Loss of Slc7a11 expression causes loss of glutathione. Total glutathi-
one was measured in five separate analyses of melan-a and sut melanocytes
grown in the absence (ME) or presence (ME) of ME (See Table 2 legend
for details). Total glutathione was93% the reduced GSH form in all analyses.
Values are mean  SEM. ***, P  0.001. ND, not detected.
Fig. 6. Ultrastructure of L-dopa-stained sut melanocytes. Melanocytes from
sut mice were cultured in the absence (A) and presence (B) of ME, stained
with dopa, and observed in the electron microscope. Arrows in A indicate
increased staining of tubularvesicle structures, possibly the trans-Golgi net-
work, typically observed in sut cells cultured without ME.
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pigment type switching. Alternatively, xCT may act in a permis-
sive role to supply enough cystine so that pheomelanin synthesis
can proceed. In this case, sut mutant melanocytes would be
expected to divert dopaquinone that would otherwise have been
converted to cysteinyl-dopa into the eumelanin branch. The
4-fold increase in eumelanin in hair of Aya, sutsut mutants is
consistent with such a role. The permissive role likewise seems
more plausible given the well documented role of xCT in cystine
transport. However, additional experiments such as the analysis
of expression of Slc7a11 mRNA during agouti banding are
required to unequivocally distinguish these possible roles.
sut cells do not proliferate or survive under normal oxidizing
culture conditions. Our data demonstrate that the xCT trans-
porter maintains normal rates of delivery of cystine into cultured
cells and thus is indispensable for cell growth and survival.
Reduced cell survival probably results from loss of critical
cellular defenses against reactive oxygen species by glutathione,
which is substantially lost in sut melanocytes, particularly under
oxidizing conditions in which cystine transport is greatly de-
pressed. These results are consistent with studies showing that
Slc7a11 expression is elevated in cells that require high gluta-
thione synthesis for antioxidant defense (17). sut cells thus
provide a model for oxidative stress-related diseases and their
therapies. We speculate that alleles of SLC7A11 may regulate
variation in human pigmentation (28, 29) as well as susceptibility
to skin cancer and other harmful effects of UV radiation (2).
Whereas Slc7a11-deficient cells in culture rapidly expire be-
cause of oxidative stress, sut mice appear healthy. A likely
explanation is that plasma, in contrast to typical culture media,
contains significant levels of cysteine (30). The widely expressed
alanine–serine–cysteine transporter (17) would be expected to
transport plasma cysteine intracellularly at levels sufficient for
viability of sut tissues. Nevertheless, cells such as melanocytes,
with attendant high cysteine requirements, manifest a mutant
phenotype in sut mice.
The oxidizing environment generated by culturing Slc7a11-
negative sutmelanocytes in the absence of MEcauses abnormal
trafficking of the critical melanosomal enzyme tyrosinase to a
perinuclear (perhaps trans-Golgi) location, although this abnor-
mality does not alter production of eumelanin pigment. Abnor-
mal trafficking of tyrosinase is apparently a general feature of
HPS, being observed in the reduced-pigmentation HPS mouse
mutant (10) and in melanocytes of HPS-1, HPS-2, and HPS-3
patients (31, 32). Whether Slc7a11 directly or indirectly regulates
trafficking of tyrosinase and other important components of
lysosome-related organelles requires further investigation.
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